Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors
Thomas De Raedt(Children's Hospital of Philadelphia), Karen Cichowski(Brigham and Women's Hospital), Clare F. Malone(Arup Group (United States)), Kwok‐Kin Wong(NYU Langone Health), Valerie S. LeBleu(The University of Texas MD Anderson Cancer Center), Danan Li(Dana-Farber Cancer Institute), Emmanuel Normant(Infinity Pharmaceuticals (United States)), Zandra E. Walton(Harvard University), Seung Min Jeong(Catholic University of Korea), Roderick T. Bronson(Harvard University), Marcia C. Haigis(Harvard University), Kay F. Macleod(University of Chicago), Brendan D. Manning(Cancer Research Center), Ophélia Maertens(American Institutes for Research), Jessica L. Yecies, Yimei Chen(University of Alberta), Raghu Kalluri(The University of Texas MD Anderson Cancer Center)
Cited by 259
Related Papers
The basics of epithelial-mesenchymal transition
|Journal of Clinical Investigation|2009|10.1k
Guidelines and definitions for research on epithelial–mesenchymal transition
|Nature Reviews Molecular Cell Biology|2020|2.3k
Epithelial-mesenchymal transition and its implications for fibrosis
|Journal of Clinical Investigation|2003|2.2k